Proponents of optical medical therapy believe that the benefits of coronary revasculartion in stable ischemic disease were established in outdated studies. But if beta blockers aren’t very effective, is optimal therapy just aspirin and a statin?

“Not all atherothrombosis is equal.” That’s the message from the latest findings of the international REACH (Reduction of Atherothrombosis for Continued Health) registry of more than 45,000 patients with “various manifestations” of atherothrombosis. According to the REACH investigators, “easily demarcated subgroups of atherothrombotic patients had widely varying risks [for future ischemic events], ranging from 7%…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.